We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




TB Screening Recommended for High-Risk Healthcare Workers Only

By LabMedica International staff writers
Posted on 08 Aug 2017
Routine screening for and treatment of latent tuberculosis (TB) infection has traditionally been an important part of TB prevention in Canadian and US healthcare institutions, but recent data have called into question its cost effectiveness. More...
A new study has found that the current strategy of annual screening of is ineffectively expensive, suggesting that a switch to screening only high-risk healthcare workers is needed.

“The background rate of TB in North American communities is much lower today than it was 25 years ago when there were epidemics of TB in cities across the United States. As such, the risk of healthcare workers being exposed and infected at work is also much lower,’’ said study corresponding author Prof. Dr. Kevin Schwartzman, of McGill University Health Centre (MUHC; Montreal, Canada), Research Institute of MUHC, and McGill International TB Centre, “Our results suggest the annual TB screening protocol should be changed to reflect more accurately the epidemiology of TB in North America and potentially in other high-income countries, such as those in Northern Europe.’’

The researchers used published data to simulate the experience of a cohort of 1,000 workers who received a baseline negative test after hiring – considering duties, tuberculosis exposure, testing and treatment. They compared the cost-effectiveness of 3 screening strategies: annual screening (for all workers with significant patient contact), targeted screening (regular screening of only the highest risk workers), and post-exposure screening (screening only after identified exposure). They considered two tests to diagnose TB infection: the tuberculin skin test (TST) and the newer QuantiFERON-TB-Gold In-Tube (QFT) test from Qiagen. The QFT test was found to be more expensive to use than the TST test, with limited or no additional benefits.

“We projected costs, morbidity, quality-adjusted survival and mortality over 20 years after hiring. One of the most striking findings was that the current annual screening strategy costs over $1.7 million to prevent one additional case of active TB in a healthcare worker, when compared to a more targeted screening strategy, which in turn costs around $400,000 more per additional case when compared to the post-exposure screening protocol,’’ said study first-author Guillaume Mullie, medical student at McGill University, “The costs of current practices are quite significant for the healthcare system, and reconsideration of this long-standing recommendation may be warranted.’’ Dr. Schwartzman added, “The more you test healthcare workers without true exposure, the more likely it is that when you do find a positive test it will be a false positive because the tests are never perfect.”

According to the researchers, healthcare workers should not be called back routinely every year for testing just because that is the protocol. Instead, only workers at a particularly high-risk (for example respiratory therapists performing bronchoscopies, or microbiology laboratory workers) should continue to be tested regularly regardless of stated exposure. Other workers should be evaluated only after exposure to a contagious patient.

“Resources currently allocated to routine TB testing for healthcare workers in North America could instead be used to increase access to prevention, treatment, and testing infrastructure and support in communities that are at higher risk of developing TB disease, such as homeless, foreign-born, and indigenous people,” said Dr. Schwartzman.

The study, by Mullie GA et al, was published May 17, 2017, in the journal BMC Medicine.

Related Links:
McGill University Health Centre
Research Institute of MUHC
McGill International TB Centre


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Pipette Management Software
VIALINK
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.